BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase II
Shire (SHPGY)'s Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation For The Treatment Of Neurocognitive Decline Associated With Hunter Syndrome 1/26/2015
Biocryst Pharmaceuticals (BCRX) Release: FDA Grants Fast Track Designation For BCX4161 For The Treatment Of Hereditary Angioedema 1/26/2015
Synageva BioPharma (GEVA) Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted 1/26/2015
Enlivex Therapeutics Ltd. Granted EU Orphan Drug Designation For Lead Product Apocell For Graft-Versus-Host Disease 1/26/2015
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015
Progenics Pharmaceuticals, Inc. (PGNX) Relaunches Pivotal Trial Of AZEDRA™ In Pheochromocytoma 1/23/2015
GlaxoSmithKline (GSK)'s Long-Awaited Ebola Vaccine Due to Arrive in Liberia 1/23/2015
Gem Pharmaceuticals Announces Enrollment Of Initial Patients In Its Phase 2 Clinical Trial To Assess The Efficacy And Safety Of GPX-150 In Sarcoma Patients 1/23/2015
CytRx Corporation (CYTR) Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma 1/22/2015
Alexza Pharmaceuticals, Inc. (ALXA) Initiates Phase 2a Study Of AZ-002 (Staccato® alprazolam) In Epilepsy Patients 1/22/2015
Medivation, Inc. (MDVN) Release: Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase In PFS As Compared To Bicalutamide In Metastatic Prostate Cancer 1/22/2015
BioMarin (BMRN), Sarepta (SRPT) Rivalry Gets Nasty in Battle Over Data 1/21/2015
Ocular Therapeutix, Inc. (OCUL) Enrolls First Patient In Phase 2 Clinical Trial For Sustained Release Dexamethasone For The Treatment Of Dry Eye Disease 1/21/2015
PharmaEngine, Inc. Announces Phase 2 PEPCOL Study Presented At The 2015 American Society of Clinical Oncology GI Of PEP02 (MM-398) In Combination With 5-FU/LV In Unresectable Metastatic Colorectal Cancer 1/21/2015
Spark Therapeutics Initiates Phase 1/2 Clinical Trial Of SPK-CHM For Choroideremia, Expanding Its Pipeline Of Potential Treatments For Rare, Blinding Conditions 1/20/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
Aduro Biotech Reports Long-Term Survival And Immune Biomarker Data From Phase 2 Clinical Trial Of Its Immuno-Oncology Regimen In Patients With Pancreatic Cancer 1/20/2015
AM-Pharma Starts Adaptive Phase 2 Trial Of Recap In Acute Kidney Injury 1/20/2015
BioInvent (BOVNF)’s Bi-1206 Antibody To Enter Collaborative Phase 1/2 Trial Funded And Conducted By Cancer Research UK, CRT And LLR 1/20/2015
Invion Limited Shows Off Positive Phase 2 Data for Smokers Trying to Quit 1/19/2015
Neurocrine Biosciences, Inc. (NBIX) Announces Granting Of Orphan Drug Status For NBI-77860 In Congenital Adrenal Hyperplasia 1/19/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
J.P. Morgan: Juno Therapeutics (JUNO) Touts 10 New Drugs for Six Diseases, Loves New CAR-T Platform 1/16/2015
Amgen (AMGN) Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer 1/16/2015
Immodulon Therapeutics Ltd Release: In IMAGE 1, A Randomised Controlled Phase 2 Clinical Trial, Administration Of IMM-101 With Gemcitabine Demonstrates Significant Survival Advantage Over Gemcitabine Alone 1/16/2015
GenSpera Announces Positive Phase 2 Data For Investigational Agent Mipsagargin 1/16/2015
Phase II Clinical Data Of Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab In Combination With Sorafenib Presented At American Society of Clinical Oncology Gastrointestinal Cancers Symposium 1/16/2015
Newron Pharmaceuticals (NWRN) Initiates Phase 2 Study Of sNN0029 In Patients With Amyotrophic Lateral Sclerosis 1/16/2015
Mesoblast Limited (MSB.AX) Reports Positive 24 Month Results In Phase 2 Trial For Chronic Low Back Pain And Initiation Of Phase 3 Program At J.P. Morgan Healthcare Conference 1/15/2015
Amarantus BioSciences, Inc. Announces Positive Data From 140 Subject LP-002 Clinical Study Of Lympro Test® Confirming Statistically Significant Markers For Alzheimer's 1/15/2015
TONIX Pharmaceuticals, Inc. (TNXP) Commences Phase 2 Trial Of TNX-102 SL In Post-Traumatic Stress Disorder 1/15/2015
PharmaCyte Biotech's Pancreatic Cancer Treatment Named As Near-Term Approach To Rising Pancreatic Cancer Rates 1/15/2015
Biocryst Pharmaceuticals (BCRX) Receives Positive Opinion On European Orphan Drug Designation For BCX4161 For The Treatment Of Hereditary Angioedema 1/14/2015
Auris Medical AG (EARS) Achieves 50% Enrollment Milestone In Post-Acute Tinnitus Stratum Of TACTT3 Clinical Trial 1/14/2015
Bellerophon Therapeutics Completes Enrollment In PRESERVATION I, A Trial Of Bioabsorbable Cardiac Matrix (BCM) For The Prevention Of Congestive Heart Failure After A Heart Attack 1/14/2015
Newron Pharmaceuticals (NWRN) Initiates Phase 2 Study Of sNN0031 In Patients With Parkinson’s disease 1/14/2015
Celsus Therapeutics (CLTX) Completes Enrollment Of Phase 2 Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis 1/13/2015
Capricor Therapeutics, Inc. Initiates The DYNAMIC Clinical Trial For The Treatment Of Advanced Heart Failure 1/13/2015
Aduro Biotech Announces Phase 2 Clinical Trial Results For Pancreatic Cancer Combination Immunotherapy Published In Journal Of Clinical Oncology 1/13/2015
Relmada Therapeutics Reaches Midway Point In Dose Escalation For Phase One Study Of Novel NMDA Receptor Antagonist D-Methadone 1/13/2015
Precision Biologics Release: NPC-1C Therapy Provides Hope For Patients With Metastatic Colorectal Cancer Showing Exciting Preliminary Results 1/13/2015
Global Blood Therapeutics Announces First Cohort Dosed In Phase 1/2 Trial Of GBT440 In Sickle Cell Disease 1/13/2015
SAGE Therapeutics Initiates Phase 2a Trial Of SAGE-547 In Postpartum Depression 1/12/2015
Anavex Life Sciences Corp. (AVXL.OB) Doses First Alzheimer's Patient In Phase 2a Trial Of ANAVEX 2-73 And ANAVEX PLUS 1/12/2015
Lion Biotechnologies, Inc. CSO Laszlo Radvanyi Co-Authors Study In Clinical Cancer Research 1/12/2015
Celator Pharmaceuticals, Inc. Announces Publication Of Promising Phase 2 Data For CPX-351 In First Relapse Acute Myeloid Leukemia Patients 1/12/2015
Clementia Opens Clinical Trial Site In Europe For Phase 2 Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva (FOP) 1/12/2015
Arena Pharmaceuticals, Inc. (ARNA) Initiates Phase 2 Clinical Trial Evaluating Ralinepag For Pulmonary Arterial Hypertension 1/12/2015
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015
Milestone Pharmaceuticals Receives FDA Clearance Of MSP-2017 Phase 2 IND 1/12/2015
TapImmune Inc. (TPIV) Release: Positive Phase 1 Immune Responses In All Evaluable Ovarian And Breast Cancer Patients Advances Vaccine To Phase 2 Clinical Trials 1/12/2015
Sorrento Therapeutics, Inc. Provides Status Update On The Cynviloq™ Registrational TRIBECA™ Study 1/12/2015
NovoCure Ltd. Announces The Completion Of Enrollment Of Its PANOVA Trial Of Tumor Treating Fields Plus Gemcitabine For Treatment Of Pancreatic Cancer 1/12/2015
FDA Approves Antria Phase 2 Stem Cell Clinical Trials 1/12/2015
Sarepta Therapeutics (SRPT) Reports Long-Term Outcomes Through 168 Weeks From Phase 2b Study Of Eteplirsen In Duchenne Muscular Dystrophy 1/12/2015
Arrowhead Research Corporation (ARWR) Provides Update On IND For ARC-520 Phase 2b Study 1/12/2015
Conatus Pharmaceuticals Inc. Announces Top-Line Results From ACLF And Organ Impairment Clinical Trials Of Emricasan 1/9/2015
SCYNEXIS, Inc. (SCYX) Receives FDA Fast Track Designation For Oral Formulation Of SCY-078 For The Treatment Of Patients With Invasive Fungal Infections 1/9/2015
Argos Therapeutics, Inc. (ARGS) Provides Update On Clinical Research For Investigational Fully Personalized Immunotherapy For The Treatment Of HIV 1/9/2015
Regen BioPharma Identifies Second Generation Gene Silencing Candidates For Blocking Cancer Stem Cell Gene Target 1/9/2015
InVivo Therapeutics Corporation (NVIV) Announces Reopening Of Enrollment For Ongoing Pilot Trial 1/9/2015
MerLion Pharmaceuticals Pte Ltd’s Finafloxacin Shows Positive Phase 2 Results In Complicated Urinary Tract Infections 1/9/2015
TRACON Pharmaceuticals, Inc. Announces Results From A Clinical Trial Of TRC105 In Patients With Hepatocellular Carcinoma To Be Presented At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/9/2015
Infinity Pharmaceuticals Inc. (INFI) to Stop Developing Rheumaid Arthritis Drug 1/9/2015
New Biogen Idec (BIIB) MS Drug May Reverse Eye Scarring 1/9/2015
MerLion Pharmaceuticals Pte Ltd’s Finafloxacin Shows Positive Phase 2 Results In Complicated Urinary Tract Infections 1/8/2015
BIND Therapeutics (BIND) Provides Clinical Update For BIND-014 And 2015 Strategic Overview 1/8/2015
Infinity Pharmaceuticals Inc. (INFI) Reports Topline Results From Phase 2 Study Of Duvelisib In Rheumatoid Arthritis 1/8/2015
Biogen Idec (BIIB) Reports Positive Top-Line Results From Phase 2 Anti-LINGO-1 Trial In People With Acute Optic Neuritis 1/8/2015
Alexion Pharmaceuticals Inc. (ALXN) Provides Update On Phase 2 Clinical Trial With Eculizumab In Antibody Mediated Rejection (AMR) In Living-Donor Kidney Transplant Recipients 1/8/2015
Bio Blast Provides Update On Clinical Trial Of Cabaletta™ For Occulopharyngeal Muscular Dystrophy (OPMD) 1/8/2015
First Patient Successfully Transplanted With Cryopreserved (Frozen) Nicord® In Gamida Cell Ltd.'s Ongoing Phase I/II Clinical Trial For Blood Cancers 1/8/2015
GW Pharmaceuticals (GWPH) Provides Update On Epidiolex® Program In Treatment Resistant Childhood Epilepsies 1/8/2015
CytRx Corporation (CYTR) Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS) 1/8/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives Clearance From Health Canada For Diabetes Clinical Trial 1/8/2015
Galapagos Starts Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients 1/8/2015
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce First Patient Treated In Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema 1/8/2015
Genervon Announces ALS Compassionate Use Results 1/8/2015
FDA Grants Soligenix (SNGX) "Fast Track" Designation For SGX301 For The First-Line Treatment Of Cutaneous T-Cell Lymphoma 1/7/2015
KaloBios Pharmaceuticals, Inc. (KBIO) Reports Top-Line Data For Phase 2 Study Of KB001-A To Treat Pseudomonas Aeruginosa Lung Infections In Cystic Fibrosis Patients 1/7/2015
Herantis Pharma Has Initiated Phase 2 Study With Cis-UCA Eye Drops In Patients With Dry Eye Syndrome, Results Expected In Q3/2015 1/7/2015
Zafgen (ZFGN) Announces Positive Results From Phase 2 Clinical Trial Of Beloranib In Hypothalamic Injury Associated Obesity 1/7/2015
Mirati Therapeutics  (MRTX) Doses First Patient In Phase 2 Study Of Mocetinostat In Bladder Cancer Patients With Genetic Alterations Of CREBBP And EP300 1/7/2015
Benitec, Inc. (BLT.AX) Advances Hepatitis C Clinical Trial 1/7/2015
ProNAi Therapeutics, Inc. Initiates Phase 2 Trial Of PNT2258 In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) 1/7/2015
Trevena, Inc. (TRVN) Initiates Second Phase 2b Study Of TRV130 For Acute Postoperative Pain 1/7/2015
Genocea Biosciences Completes Enrollment Early In Phase 2 Dose Optimization Trial Of GEN-003 For Treatment Of Genital Herpes 1/7/2015
Kadmon Corporation Initiates Phase 2 Clinical Trial Evaluating KD025 In Psoriasis 1/7/2015
Otic Pharma Announces Positive Results From A Phase 2 Trial Of Foamotic Externa, Once-A-Day, Single Antibiotic, Steroid Free Product For Acute Otitis Externa (AOE) 1/7/2015
Alkermes plc (ALKS) Announces Positive Results Of Phase 2 Clinical Trial Of ALKS 3831 In Schizophrenia 1/7/2015
CytRx Corporation (CYTR)'s Brain Cancer Drug Shows Promise in Mid-Stage Study 1/6/2015
CytRx Corporation (CYTR) Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer) 1/6/2015
Mast Therapeutics (MSTX) Provides Update On Epic Study Enrollment And 2015 Milestones 1/6/2015
Ultragenyx Pharmaceuticals (RARE) Initiates New Development Program Studying KRN23 For The Treatment Of Tumor-Induced Osteomalacia 1/6/2015
Tobira Therapeutics Inc.' Cenicriviroc Granted Fast Track Designation By The FDA For The Treatment Of Nonalcoholic Steatohepatitis (NASH) In Patients With Liver Fibrosis 1/6/2015
Clearside Biomedical Initiates Phase 2 Clinical Trial For The Treatment Of Macular Edema Associated With Non-Infectious Uveitis 1/6/2015
Akebia Therapeutics, Inc. (AKBA) Completes Enrollment In The Two Planned Cohorts Of Its Phase 2 Study Of AKB-6548 In Patients With Anemia Related To Chronic Kidney Disease Undergoing Dialysis 1/6/2015
Ariad Pharmaceuticals, Inc. (ARIA) Announces Phase 2 Dose-Ranging Trial Of Iclusig (Ponatinib) To Begin By Mid-2015 1/6/2015
Gamida Cell Ltd.'s NiCord® Receives FDA And European Medicines Agency Orphan Drug Designation 1/6/2015
Cellular Biomedicine Group (CBMG) Initiates Patient Recruitment For Cartilage Damage Stem Cell Therapy Clinical Research Study 1/6/2015
Versartis, Inc. (VSAR) Announces Positive 12 Month Data For VRS-317 from Ongoing Extension Study 1/5/2015
Lion Biotechnologies, Inc. Submits Investigational New Drug Application To Conduct Phase 2 Study In Metastatic Melanoma 1/5/2015
Immunomedics, Inc. (IMMU) Awarded Fast Track Designation By FDA For Sacituzumab Govitecan (IMMU-132) For Triple-Negative Breast Cancer Therapy 1/5/2015
University of California, Los Angeles (UCLA) Launches Phase 2 Pediatric Clinical Trial For The Treatment Of ADHD With NeuroSigma, Inc.'s eTNS System 1/5/2015
Conatus Pharmaceuticals Inc. To Report Top-Line Results From ACLF And Organ Impairment Clinical Trials Of Emricasan 1/5/2015
BrainStorm Cell Therapeutics Inc. Announces Final Analysis Of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit From NurOwn™ 1/5/2015
ReVance Therapeutics, Inc. (RVNC) Announces Initiation Of BELMONT Phase 2 Active Comparator Trial Of Injectable RT002 1/5/2015
Cellceutix (CTIX) Releases Confidence Interval Statistics Showing Clinical Success Rates For Brilacidin In Treatment Of ABSSSI 1/5/2015
NeuroDerm Ltd. (NDRM) Shares Double as Parkinson's Drug Shows Promise in Phase 2 Study 1/2/2015
Aquinox Pharmaceuticals (AQXP) Initiates Patient Dosing In The Phase 2 Clinical Trial Of AQX-1125 In Atopic Dermatitis 12/31/2014
NephroGenex (NRX) Announces Positive Results For QT Study Of Pyridorin 12/31/2014
NeuroDerm Ltd. (NDRM) Announces Topline Results Of Phase 2a Pharmacokinetic Study Of ND0612H And ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease 12/31/2014
Repros Therapeutics Inc. (RPRX) Initiates Two Phase 2B Uterine Fibroid Studies 12/30/2014
Ignyta (RXDX) Receives Orphan Drug Designation And Rare Pediatric Disease Designation From FDA For Entrectinib For The Treatment Of Neuroblastoma 12/29/2014
Athersys, Inc. (ATHX) Finishes Enrollment Of Phase 2 Study Of Multistem® Cell Therapy For Ischemic Stroke 12/29/2014
Versartis, Inc. (VSAR) To Hold Conference Call To Discuss VRS-317 Clinical Update From Ongoing Extension Study 12/29/2014
RegeneRx Biopharmaceuticals, Inc. (RGRX) Partner Submits Phase 2B/3 IND To Korean Health Authority For RGN-259 For The Treatment Of Dry Eye Syndrome 12/29/2014
Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells (STEM), Cellular Dynamics 12/24/2014
Biocryst Pharmaceuticals (BCRX) Receives Orphan Drug Designation For BCX4161 For The Treatment Of Hereditary Angioedema 12/24/2014
Achillion Pharmaceuticals, Inc. (ACHN) Surges as Potential Drug Combo Seen as Hepatitis C Cure 12/23/2014
NeuroLifeSciences Release: Redefining ADHD: A New Approach & A Shift Of Paradigm In ADHD Therapeutics 12/23/2014
Provectus Biopharmaceuticals Inc.’ Protocol For Phase 2 Study Of Mechanism Of Action Of PH-10 On Immunologic Makers Of Psoriasis Now Available Online 12/23/2014
BioTie Therapies Corp. Announces Start Of Syn120 Phase 2a Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events 12/23/2014
Cellceutix (CTIX) Reports Positive Results Of Brilacidin In Microbiological Intent-To-Treat Population In Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information To Be Submitted 12/23/2014
Achillion Pharmaceuticals, Inc. (ACHN) Shows Potential For "Best-In-Disease" HCV Regimen - 100% SVR4 Following A Dual 6-Week ACH-3102-Based Regimen And Separately A 4.8 Log10 Reduction With ACH-3422 12/22/2014
VBL Therapeutics (VBLX) Announces Positive Phase 2a Data For VB-111 In Recurrent Thyroid Cancer 12/22/2014
FDA Grants Orphan Drug Designation To Nuvilex (NVLX) For Pancreatic Cancer Treatment 12/22/2014
Can-Fite BioPharma (CFBI) Doses First Patient In Global Phase 2 Liver Cancer Trial For CF102 12/22/2014
Eiger Bio Announces Positive Data In Patients Infected With Hepatitis Delta Virus (HDV) Treated With Lonafarnib - Results Presented At American Association for Study of Liver Diseases Meeting 12/22/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Reaches Response Milestone In Phase 2 Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome 12/22/2014
MediGene AG (MDGEF.PK) Receives Clinical Trial Approval For Phase I/II Study With DC Vaccine To Treat Acute Myeloid Leukaemia (AML) 12/22/2014
Cerus Corporation (CERS) Reports U.S. Phase 2 Clinical Trial Of INTERCEPT Red Blood Cells Met Primary Endpoint 12/22/2014
Second Phase Of GlaxoSmithKline (GSK)'s Ebola Vaccine Delayed 12/22/2014
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation In The United States And The European Union For The Treatment Of Malignant Pleural Mesothelioma 12/19/2014
AB Science (AB.PA): Report Of Positive Clinical Study Data In Metastatic Colorectal Cancer 12/19/2014
Innate Pharma (IPH.PA ): First Phase 2 Trial With IPH2201 Open In Head And Neck Cancer 12/19/2014
Amarantus BioSciences, Inc. Submits Orphan Drug Designation Application To U.S. FDA For Treatment Of Retinal Artery Occlusion With Product Candidate MANF 12/19/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Results From The Phase 2 Borealis-1 Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer 12/19/2014
Halozyme Therapeutics, Inc. (HALO) Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer 12/19/2014
Xenetic Biosciences Completes Enrollment Of Second Cohort In Phase 2a Study With Erepoxen® For Anemia; Hemoglobin Levels Rise Into Therapeutic Range Over Time 12/19/2014
TetraLogic Pharmaceuticals (TLOG) Announces Initiation Of A Randomized Phase 2 Clinical Trial Of SHAPE In Subjects With Cutaneous T-Cell Lymphoma 12/18/2014
Fate Therapeutics (FATE) Announces Interim Data From Ongoing Phase 2 PUMA Study 12/18/2014
Biocryst Pharmaceuticals (BCRX) Initiates Opus-2: A Clinical Trial Of BCX4161 In Patients With Hereditary Angioedema 12/18/2014
StemCells Inc. (STEM) Transplants First Participant In Phase 2 Clinical Trial In Cervical Spinal Cord Injury 12/18/2014
Nuvo Research Inc. (NRI.TO) Reports That All Patients Have Completed Phase 2 Study Of WF10 For The Treatment Of Allergic Rhinitis 12/18/2014
D-Pharm Ltd. Achieves Primary End-Point In Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 12/18/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Release: Study Further Validates Cell Therapy Approach To Reverse Type 1 Diabetes 12/18/2014
Ablynx (ABLYF) Opens Recruitment For First-In-Infant Phase 2a Study With Its Anti-Rsv Nanobody, ALX-0171 12/17/2014
Stemline Therapeutics, Inc. (STML) Initiates SL-401 Clinical Trial In Four Rare Myeloproliferative Neoplasms 12/17/2014
RXi Pharmaceuticals (RXII) Announces Sustained Effect Of RXI-109 At Three Months Post Scar Revision Surgery And The Completion Of Enrollment For Its Phase 2a Trial RXI-109-1301 12/17/2014
Pfizer (PFE) Initiates Phase 2 Study Of PF-06252616 In Duchenne Muscular Dystrophy 12/17/2014
Pivotal Therapeutics Inc. Release: VASCAZEN POMEGA Phase 2a Trial Protocol Cleared Clinical Evaluation By French FDA 12/17/2014
Velocity Pharmaceutical Development And Tigercat Pharma, Inc. Announce Phase 2 Results For VPD-737 In Patients With Chronic Pruritus 12/17/2014
First Patient Treated In Mapi Pharma's Phase 2a Clinical Trial Of GA Depot For Relapsing Remitting Multiple Sclerosis (RRMS) 12/17/2014
Poxel Announces Positive Top Line Results For Its Antidiabetic Agent Imeglimin In A Phase 2b Dose-Ranging Trial 12/17/2014
Neovacs SA Announces Top Line Phase 2b Clinical Trial Results Of TNF-Kinoid In Rheumatoid Arthritis And Update On Clinical Programs 12/16/2014
Anavex Life Sciences Corp. (AVXL.OB) Begins Enrollment Of Alzheimer's Patients In Phase 2a Clinical Trial Of ANAVEX 2-73 And ANAVEX PLUS 12/16/2014
Galapagos NV (GLPG.BR) Regains Full Rights To GPR84 Inhibitor GLPG1205 12/16/2014
GENFIT Corp. (ALGFT): Gft505 Treatment Prevents Evolution To Cirrhosis 12/16/2014
SOV Therapeutics Announces Successful Phase 2b Study Of Oral Testosterone Undecanoate For Treatment Of Primary And Secondary Hypogonadism In Adult Males 12/16/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1/2 Study Of ISIS-DMPK Rx In Patients With Myotonic Dystrophy Type 1 12/16/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANEв Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer 12/16/2014
Bone Therapeutics Confirms Safety In ALLOB® Phase 1/2a Trial For Delayed-Union Fractures 12/16/2014
Why Gilead Sciences, Inc. (GILD) And AbbVie (ABBV) Are Keeping An Eye On Achillion Pharmaceuticals, Inc. (ACHN) 12/15/2014
VBL Therapeutics (VBLX) Announces Last Patient Out In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 12/15/2014
Zafgen (ZFGN) Announces Initiation Of Phase 2b Trial Of Beloranib In Severe Obesity 12/15/2014
Araim Pharmaeuticals Release: New Study Published In Molecular Medicine Reports That Novel Agent Decreases Neuropathic Pain In Patients With Type 2 Diabetes 12/15/2014
Ascendis Pharma A/S Announces Positive Six-Month Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 12/15/2014
Can-Fite BioPharma (CFBI) Release: Second Part Of The Glaucoma Phase 2 Study Has Been Approved In A European Country 12/15/2014
Taiwan's TWi Biotech To Start Clinical Trial Of Gout Treatment 12/15/2014
Vaxil Publishes The Results Of Its Phase 1/2 Study Using Immucin In Myeloma Patients In The "British Journal Of Hematology" 12/15/2014
Astellas Pharma Inc. (ALPMY) Release: Data Presented From Phase 2 Study Of Enzalutamide In Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer 12/15/2014
ChemoCentryx, Inc. (CCXI) Announces Positive Results In Phase 2 Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140 12/12/2014
ChemoCentryx, Inc. (CCXI)To Host Conference Call On Friday, December 12, 2014 To Discuss Top-Line Phase 2 Results In Patients With Diabetic Nephropathy With CCX140, An Orally Administered CCR2 Inhibitor 12/12/2014
TWi Pharmaceuticals, Inc. Receives Approval Of Protocol For Its Drug Ac-201 Controlled-Release Tablet, Phase 2 Clinical Trial In Both The United States And Taiwan 12/12/2014
Merck & Co. (MRK),NewLink Genetics Ebola Trial Suspended After Patients Complain Of Joint Pain 12/12/2014
Kamada Ltd. (KMDA) Announces Positive Interim Results From Phase 1/2 Clinical Study Of Its Human Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease Presented At American Society of Hematology Annual Meeting 12/11/2014
Karyopharm Therapeutics (KPTI) Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330) 12/11/2014
International Breast Cancer Study Group, Breast International Group And Merck & Co. (MRK) Announce Opening Of International PANACEA Study Of Patients With HER2+ Breast Cancer 12/11/2014
Cellceutix (CTIX): Prurisol™ For Psoriasis -- FDA Agrees That Phase 2 Study May Begin 12/11/2014
Neurovance Announces Top-Line Study Results Suggest Lower Abuse Potential For Centanafadine Compared To Stimulants Used For Adult ADHD 12/11/2014
ARCA biopharma Announces Activation Of First Canadian Genetic-AF Clinical Trial Site 12/11/2014
FDA Grants BioMarin Pharmaceutical Inc. (BMRN) Orphan Drug Designation For NAGLU Fusion Protein, BMN 250, For The Treatment Of MPS IIIB (Sanfilippo Syndrome Type B) 12/10/2014
International Breast Cancer Study Group, Breast International Group And Merck & Co. (MRK) Announce Opening Of International PANACEA Study Of Patients With HER2+ Breast Cancer 12/10/2014
Naurex Inc.'s GLYX-13 Demonstrates Robust, Sustained Antidepressant Effects And Excellent Tolerability In Phase 2b Study 12/10/2014
Merck Announces Positive Data Investigating The Use Of Pembrolizumab In Patients With Advanced Triple-Negative Breast Cancer At 2014 San Antonio Breast Cancer Symposium 12/10/2014
Celgene (CELG) Release: Combination Of ISTODAX® (Romidepsin) And Standard CHOP Demonstrates A Complete Response In 51% Of Patients With Peripheral T-Cell Lymphoma 12/10/2014
Marina Biotech, Inc. (MRNA) Reports That Licensee ProNAi Therapeutics, Inc. Presented Interim Phase 2 Data On Its BCL2-Targeting DNAi® Therapeutic At American Society of Hematology 2014 12/10/2014
Ironwood Pharmaceuticals (IRWD) Initiates Phase 2a Clinical Study Of IW-9179 In Diabetic Gastroparesis 12/9/2014
Celgene (CELG) Release: REVLIMID® (Lenalidomide) Single-Agent And Combination Studies In Mantle Cell Lymphoma (MCL) Presented At American Society of Hematology 12/9/2014
OncoSec Medical Inc. Announces New Phase II Trial In Head And Neck Cancer Using ImmunoPulse 12/9/2014
Bristol-Myers Squibb Company (BMY), Merck & Co. (MRK) Drugs Effective In Hodgkin Lymphoma Trials 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) In Combination With Rituximab Data Shows Positive Benefit-Risk Profile In Hematologic Malignancy 12/9/2014
Amgen (AMGN) Presents Data From Pivotal Phase 2 Study Of BLINCYTO (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Data Demonstrates Safety And Durability Of Response At Two-Year Follow-Up In Mantle Cell Lymphoma 12/9/2014
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Long-term Follow-up Data In Patients Living With Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive At Two Years 12/9/2014
Kiadis Pharma Presents Positive Data From A Pre Specified Interim Analysis Of The Phase 2 Clinical Program With Its Lead Product ATIR 12/9/2014
Promedior Presents Positive Phase 2 Data For PRM-151 In Myelofibrosis At American Society of Hematology Annual Meeting 12/9/2014
TG Therapeutics, Inc. (MHA) Release: Data From Phase 2 Clinical Trial Of TG-1101 (Ublituximab) And Ibrutinib Shows Compelling Clinical Activity In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 12/9/2014
Celgene (CELG) Release: New Data In Myelodysplastic Syndromes Presented At The 56th American Society of Hematology Annual Meeting And Exposition 12/9/2014